AN ANALYSIS OF THE united states IMMUNOGLOBULIN (Ivig & scig) MARKET IN 2021
AND FORECAST TO THE YEAR 2030
As immunoglobulin (IG) is the dominant revenue-generating therapeutic protein from plasma fractionation, its future growth rate profoundly impacts the entire industry on a number of levels, including plasma requirements forecasting, plasma collection capacity planning, manufacturing infrastructure planning, projection of per-liter plasma valuation, and revenue and profit forecasting. For these and other reasons, projection of the likely future demand for IG is of critical importance.
This new report provides a complete update to a report last published in 2019 and takes a deep look at current IVIG and SCIG usage by medical indication and channel (hospital, infusion suite and specialty pharmacy) for the year 2021. It has separate usage for IVIG and SCIG, as well as the total IG usage in the country. Using this data from various sources, the report forecasts the usage of each medical indication annually to 2030, for IVIG and SCIG separately, and also by channel.
MRB’s forecast model analyzes both key drivers of IG growth and risks to future growth, taking into account how the interaction of plasma supply and IG demand can be expected to influence price patterns over the next 8 years.
Compared with a few years ago, there is increasing realization that new competition to IG usage in several autoimmune conditions including Myasthenia Gravis, ITP and CIDP is important to understand and properly account for. Already one product for Myasthenia Gravis is approved and gaining patients, but the amount of patients and its impact on IG usage in Myasthenia Gravis, ITP and CIDP are investigated in detail in this report.